Depression in pulmonary arterial hypertension: An undertreated comorbidity

Sameer Verma, Sonu Sahni, Vannan K Vijayan, Arunabh Talwar

Department of Pulmonary, Critical Care and Sleep Medicine, North Shore - Long Island Jewish Health System, New York, USA

Department of Medicine and Chest Diseases, Clinical Support Services, Baby Memorial Hospital, Kozhikode, Kerala, India

ABSTRACT

Pulmonary arterial hypertension (PAH) is a debilitating condition leading to progressive decline in functional capacity. As a result, PAH can lead to psychological impairment that can impact the overall disease status. The medical community has developed several screening questionnaires in order to assess depression in their patients allowing physicians to be at the forefront of recognizing clinical depression. There is a suggestion that depression symptomatology is more prevalent in the PAH population. The aim of this article is to review the current thought process about diagnosis and management of depression in PAH patients.

KEY WORDS: Depression, psychotherapy, pulmonary arterial hypertension, pulmonary rehabilitation screening questionnaire

INTRODUCTION

Pulmonary arterial hypertension (PAH) is a debilitating lung disease characterized by persistent elevation of pressure in the pulmonary arteries and pulmonary vascular resistance leading to right heart failure resulting in a progressive decline in the level of functioning.\(^1\) Patients present with increased shortness of breath on exertion, palpitations, and fatigue, making it difficult to differentiate these symptoms from other cardiopulmonary diseases. Medical research in the past three decades has changed management approach to this disease and today medical therapies such as prostanoids, phosphodiesterase type-5 inhibitors (PDE-5) and endothelin receptor antagonists (ERAs) are available to improve exercise tolerance.\(^2\) These medications have reduced mortality and improved exercise capacity and pulmonary hemodynamic parameters.\(^2\) Despite these innovations, it is recognized that the debilitating natural history of PAH provides a significant challenge for patients and physicians.\(^3\) PAH patients suffer from many comorbidities. Depression remains one such prominent comorbidity. The aim of this article is to review the current literature of depression in PAH.

RESEARCH IN PULMONARY ARTERIAL HYPERTENSION AND DEPRESSION

Depression is a serious illness characterized by an intense feeling of sadness associated with emotional and behavioral changes affecting anyone regardless of age, race, gender, or socioeconomic status. Patients can feel (a) hopelessness (b) helplessness (c) worthlessness (d) agitation (e) fatigue (f) lack of interest (g) decreased concentration (h) suicidal thoughts, and (i) appetite changes.\(^4\) A clinical diagnosis of depression requires patients to have five or more of the nine symptoms in a 2-week period.\(^4\) These symptoms have a significant effect on the patient's level of functioning and as a result, interfere with daily activities.\(^4\) Depression may be difficult to detect because of lack of specific laboratory parameters pointing toward it. In clinical practice, depression can also...
Table 1: Major studies of PAH and depression

| Trial/Year                | Study design | N       | Screening instruments | Results                                                                 |
|--------------------------|--------------|---------|-----------------------|-------------------------------------------------------------------------|
| Shafazand et al./2004[16] | Cross-sectional | 53 PAH† | (NHP)* Congestive heart failure questionnaire (CHFQ)** | Moderate to severe anxiety (20.5%) and depression (7.5%) |
|                          |              |         | Hospital anxiety and depression Scale (HADS)*** | 29% accept risk of death                                                 |
|                          |              |         |                       | Moderate to severe impairment in NHP domain                              |
|                          |              |         |                       | Moderate to severe impairment in HRQoL††† domains                        |
|                          |              |         |                       | Patients on epoprostenol had more energy, less emotional stress           |
| Lowe et al./2004[11]     | Cross-sectional | 164 PH† | PHQ-9* | 58/164 (35%) of PH patients had MD*** |
|                          |              | 164 IRDs†† |                      | Major depression (15.9%)                                                 |
|                          |              | 164 PC††  |                      | Panic disorder (10.4%)                                                   |
|                          |              |         |                       | Patients who were given no epoprostenol had more anxiety and depression  |
|                          |              |         |                       | 58/164 (35%) of PH patients had MD*** | More MD is PH patients compared to IRDs (27.4%) and PC (24.4%) |
|                          |              |         |                       | Major depression (15.9%)                                                 |
|                          |              |         |                       | More MD is PH patients compared to IRDs (27.4%) and PC (24.4%) |
|                          |              |         |                       | Prevalence of depression/anxiety strongly associated with declining NYHA FC |
|                          |              |         |                       | 14/58 (24.1%) received psychiatric meds                                  |
|                          |              |         |                       | 45% with work disability                                                  |
|                          |              |         |                       | 27/46 (58%) had cognitive sequelae                                       |
|                          |              |         |                       | 26% moderate to severe depression                                         |
|                          |              |         |                       | 19% moderate to severe anxiety                                            |
|                          |              |         |                       | Decreased QoL with worse working memory                                   |
|                          |              |         |                       | 21% moderate to severe depression                                         |
|                          |              |         |                       | Moderate to severe depression with worse physical functioning            |
|                          |              |         |                       | 15% patients had major depression                                         |
|                          |              |         |                       | 40% patients had mild to moderate depression                              |
|                          |              |         |                       | 45% patients had no- to- minimal depressive symptoms                      |
|                          |              |         |                       | 23/90 (25%) patients on antidepressant therapy                           |
|                          |              |         |                       | 22.8% patients had moderate to severe anxiety or depression               |
|                          |              |         |                       | Moderate to severe MD*** had lower QoL‡‡§§§§                      |
|                          |              |         |                       | 8% received psychiatric meds                                              |
| White et al./2006[13]    | Cross-sectional | 46 PAH† | Cognitive scales BDI* | 45% patients had no- to- minimal depressive symptoms                      |
|                          |              |         |                      | 22.8% patients had moderate to severe anxiety or depression               |
|                          |              |         |                       | Moderate to severe depression with worse physical functioning            |
|                          |              |         |                       | 15% patients had major depression                                         |
|                          |              |         |                       | 40% patients had mild to moderate depression                              |
|                          |              |         |                       | 45% patients had no- to- minimal depressive symptoms                      |
|                          |              |         |                       | 23/90 (25%) patients on antidepressant therapy                           |
|                          |              |         |                       | 22.8% patients had moderate to severe anxiety or depression               |
|                          |              |         |                       | Moderate to severe MD*** had lower QoL‡‡§§§§                      |
|                          |              |         |                       | 8% received psychiatric meds                                              |
| Looper et al./2009[22]   | n/a          | 52 PH†  | BDI* SF 36*** | Decreased QoL with worse working memory                                   |
| McCollister et al./2010[14] | Observational | 100 PAH† | PHQ-8* | 21% moderate to severe depression                                         |
| Harzheim et al./2013[15] | Prospective  | 158 patients | SF 36*** | 21% moderate to severe depression                                         |
|                          |              | 138 PAH† | PHQ-9* | Moderate to severe depression with worse physical functioning            |
|                          |              | 20 CTEPH | GAD-7* | Moderate to severe MD*** had lower QoL‡‡§§§§                      |

PAH: Pulmonary arterial hypertension, NHP: Nottingham health profile, CHFQ: Congestive heart questionnaire, HADS: Hospital anxiety and depression Scale, HRQoL: Health related quality of life, PH: Pulmonary hypertension, IRDs: Inflammatory rheumatic diseases, PC: Primary care, PHQ: Patient health questionnaire, MD: Mental disorder, BDI: Beck depression inventory, BAI: Beck anxiety inventory, SF 36: Short form 36 health survey, PHQ-8: Patient health questionnaire 8, PHQ-9: Patient health questionnaire 9, GAD-7: Generalized anxiety disorder questionnaire 7, QoL: Quality of life

be sometimes difficult to diagnosis because of the overlap of symptoms between depression and medical conditions.[5] Even when patients meet the criteria of depression, the stigma and misconceptions associated with it can make them skeptical about openly seeking help or having an open discussion with health care providers.

The association between depression and PAH has been established [Table 1]. Once a diagnosis of PAH is confirmed, patients have to cope with mixed emotions of understanding and accepting the reality in conjunction with adjustment to their condition [Figure 1]. The complex nature of PAH, an uncertain future, and a lack of cure can impel feelings of being overwhelmed and the inability to maintain regular social activities.[6,7] As a result, patients report restrictions in their ability to perform daily tasks such as working, traveling, shopping, and household chores.[10] A recent international survey of PAH patients found them to have feeling of worthlessness (22%), frustration (35%), anger (24%), and little pleasure in activities (25%) that they enjoyed prior to PAH diagnosis.[11] As patients struggle to cope with an unfamiliar condition, they are frustrated in keeping up with their doctor’s appointment, magnitude of multiple tests, and expenses associated with PAH management. Additionally, poor sleep quality is common among these patients and it is related to dyspnea, depression, and quality of life (QoL).[17] This insurmountable burden can serve as a medium for self-doubt and noncompliance with medication, which in effect raises health care costs.

Shafazand et al. conducted a study that used Nottingham Health Profile (NHP), Congestive Heart Failure Questionnaire (CHFQ), with Hospital Anxiety and
Depression Scale (HADS) as a component to access overall health-related QoL in PAH patients.\textsuperscript{[14]} A total of 53 patients [mainly New York Heart Association (NYHA) functional class III and IV] were included in the study and were divided into treatment (53% on epoprostenol therapy) and no treatment (47% no epoprostenol therapy) groups. The patient group not on therapy had significantly more anxiety and depression as compared to the medication group. On average, PAH patients reported moderate to severe degree of impairment in all domains of the QoL such as social isolation and emotional reaction. Participants were so unhappy with their lifestyles that (29%) were prepared to take a risk of death in order to be free of the symptoms of PAH.\textsuperscript{[10]}

Lowé et al. investigated the prevalence of anxiety and depression in pulmonary hypertension (PH) patients.\textsuperscript{[11]} In this study, 164 patients were matched in two comparison groups, inflammatory rheumatic diseases (IRDs) and primary care (PC) patients, who completed a standardized, validated and self-administered patient health questionnaire (PHQ). The study found that patients with PH were diagnosed with one or more mental disorders such as anxiety and depression more commonly compared to IRD and PC patients.\textsuperscript{[11]} There was also evidence that in PAH patients, as the functional class declined, the frequency of mental disorders increased from (17.7%) in NYHA (Class I) to (61.9%) in NYHA (Class IV). Of the patients, 24.1% received some kind of treatment for their mental disorder.\textsuperscript{[11]} Thus, there was also a strong association between increasing functional impairment and mental disorders.

Looper et al. investigated depressive symptoms and its association with the physical symptoms of PH.\textsuperscript{[12]} Fifty-two patients, both precapillary and postcapillary PH patients, who were included in this trial completed the beck depression inventory (BDI) questionnaire for depression and it was found that physical functioning was significantly associated with depressive symptoms. Moderate to severe depression significantly worsened physical function scores in comparison to minimal or no depressive symptoms.\textsuperscript{[12]} White et al. evaluated emotional and cognitive impairments in PAH patients. BDI questionnaire was used in 46 patients and it was found that 26% of the patients had some symptoms of moderate to severe depression.\textsuperscript{[13]}

McCollister et al. studied the prevalence of depression in a PAH as a primary endpoint, using PHQ-8.\textsuperscript{[14]} A total of 100 patients were enrolled in the trial and at two separate outpatient visits, the questionnaires were completed and functional class assessment and 6-min walk distance (6MWD) were performed. A high prevalence of depressive symptoms (55%) was found in this study population but only 25% of the patients were taking any type of antidepressant medication.\textsuperscript{[14]} This study highlighted that depression treatment was being underutilized in this population.\textsuperscript{[14]}

Harzheim et al. demonstrated that moderate to severe depression was significantly correlated with a lower QoL but not with long-term survival.\textsuperscript{[15]} This prospective study of 158 patients with PAH and chronic thromboembolic pulmonary hypertension (CTEPH) patients used PHQ-9 and Generalized Anxiety Questionnaire-7 (GAD-7) for assessment. Patients with a high GAD-7 value also had a high PHQ-9 value, thus suggesting a significant correlation between the severity of anxiety and depression disorders.\textsuperscript{[15]} In addition, 57.6% of the patients with moderate to severe mental disorder had significant impairment in their daily activities, as compared to patients with no or mild depression (11.7%). Among the patients, 22.8% presented with moderate to severe anxiety or depression and out of them, only 8% were receiving any psychopharmacological treatment.\textsuperscript{[15]} A recent cross-sectional survey was performed to examine the corelation of depression, anxiety, and its effects on 6MWD and health-related quality of life (HRQoL) in PH patients.\textsuperscript{[16]} Tartavoule et al. conducted a survey of 166 patients by completing Depression Anxiety Stress Scale (DASS) and the Dartmouth Cooperative Functional Assessment Charts. The findings of this survey were indicative of a link between stress anxiety and QoL with PH.\textsuperscript{[16]}

**SCREENING FOR DEPRESSION**

Screening for depression in the PAH population remains challenging because depressive symptoms such as low energy or fatigue can be viewed as part of the underlying disease process. Therefore, they can sometimes be ignored. A lack of proper training skills in treating physicians may also play a role in not detecting underlying depression.\textsuperscript{[7]}

Recently, the US Preventive Services Task Force has recommended health care providers to screen and provide effective treatment for depression in adult patients.\textsuperscript{[17]} One method of screening for depression is to utilize questionnaires that have been developed over the years. These questionnaires have been validated by research and extensively used in many chronic conditions.\textsuperscript{[18]} Some of the screening tools available are Zung Self-rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), PHQ-9, and BDI.\textsuperscript{[19]} These scales are simple to complete and can be done while patients are waiting in doctors’ offices to be seen by a physician. Patients suspected of depression, based on the screening questionnaires, should therefore, undergo a thorough assessment to determine the presence or severity of depression. As patients are being assessed for depression, risk of suicide should be assessed very meticulously by their physicians.

**MANAGEMENT OF DEPRESSION IN PULMONARY ARTERIAL HYPERTENSION**

Depression is a treatable condition. However, the exact pharmacotherapy for treatment for a PAH patient needs to be well-defined. There is limited and contentious data...
on the use of certain antidepressants such as selective serotonin reuptake inhibitors (SSRIs) for PAH patients. Kawut et al. performed a retrospective study of 84 patients, out of which 13 patients were taking SSRIs. The study observed that PAH patients had a lower risk of death (50%) compared to those not treated with SSRIs. These findings were inconsistent with other reports. Sadoughi et al. explored the relationship between SSRIs and PAH. PAH patients taking SSRIs were at high risk of mortality and clinical worsening than patients not taking SSRIs. Huybrechts et al. examined the association between high morbidity pregnancy and antidepressant medication usage leading to the development of persistent pulmonary hypertension of the newborn (PPHN). The finding of this large cohort suggests that SSRIs exposure in late pregnancy is associated with increased risk of PPHN; however, the risk was found to be smaller than what was previously proposed.

The best treatment for depression in PAH patients is not known. PAH patients are already on multiple medications and it conceivably raises the possibility of assessing a nonpharmacological outlook for the treatment of depression. As part of an integrative approach to depression, guidelines are available to efficiently treat it with medication and psychotherapy. Current guidelines for depression in the general population recommend the usage of a combination of medication and psychotherapy for moderate to severe depression while psychotherapy along with this can be a valuable first step for mild depression. However, whether this applies for PAH patients or not has not been studied. Psychotherapy is an effective form of treatment for depression that allows patients to converse with a health care professional. It is a method that helps patients to understand their behavior that might have contributed to depression. One particular form of psychotherapy is cognitive behavioral therapy (CBT). The basic principal of CBT is a focused, structured collaborative environment to assist patients in solving problems and dysfunctional thinking. It is a collaborative effort between patients and clinicians to apply valuable strategies that can help patients to gain control. Such strategies have been used in chronic obstructive pulmonary disease (COPD) patients. However, there is a paucity of data regarding CBT in the PAH cohort.

In addition to behavioral therapy, support groups can also be considered as part of a new innovative option for patients. Support groups are voluntary gatherings of patients and their family members that allow them to share their personal experiences with other patients. It is an opportunity to simultaneously provide and receive support, build acquaintances, and share coping strategies. A well-functioning support system can empower patients to manage their condition more wholeheartedly. Support groups can have a positive impact on the motivation, confidence, and general well-being of the patient.

Flattery et al. illustrated that patients actively seek support groups as a way of learning about the disease and methods to cope with the uncertainty associated with it.

More recently, pulmonary rehabilitation (PR) has emerged as an important and integral part of clinical management of chronic respiratory diseases. There is evidence that PR improves function, disease symptoms, fatigue, and QoL in COPD and CHF patients. PR has been commonly used as a part of standard of care in COPD and CHF patients. Our own data support the perception of improvement in fatigue in advance lung disease after the completion of a PR program. Talwar et al. found in a cohort of 21 patients a significant improvement in fatigue and suggested an improvement in depression symptoms after completing PR. There is an increasing thought process that pulmonary exercise may be beneficial in these patients and clinical data are suggestive of the usage of PR in improving depression. Mereles et al. evaluated the effects of daily exercise in a 15-week trial of 36 patients. At the end of 15 weeks of PR, there was a mean improvement of 111 m in the 6MWD. Exercise training was associated with significant improvement in the QoL as measured by SF-36 questionnaire. The effects of PR on inspiratory muscle training have also been recently investigated. Saglam et al. recruited 29 stable PAH patients who were either in a inspiratory muscle training (IMT) group or a control group for 6 weeks and their QoL was assessed by Nottingham Health Profile (NHP). After completion of PR, patients in the IMT group had considerable improvement in muscle strength as well as emotional and psychosocial dynamics. Another contemporary approach as an adjunctive therapy for anxiety and depression is progressive muscle relaxation (PMR) techniques, PMR is technique developed to relax various body muscles in order to manage anxiety and stress. Li et al. recruited 130 PAH patients who were randomized to be either the control group or treatment group for 12 weeks. In comparison to the controls, the study found that patients in the treatment arm had significant improvement in depression and overall QoL.

MOVING FORWARD

Managing important comorbidities is an important aspect of treating any disease with poor outcome. A similar conclusion can made in the case of PAH. This coexistence of PAH and depression presents health care workers with a challenge but also an opportunity. It is a challenge because of lack of appropriate guidelines for confronting depression with PAH and therefore, leaving its treatment to the clinical judgment of physicians and patient preference. Limited studies have highlighted its significance; the exact association has not been fully addressed. Unfortunately, large scale clinical trials at times may not be possible because of competing illnesses, limited resources, and infrastructure. In such cases, conducting observational studies is beneficial in identifying PAH patients with depression.
It is also the right opportunity for health professionals to focus on a) obstacles in diagnosing depression, b) addressing obstacles in treating depression, and c) clarifying the ideology of using depression as an outcome measure and its relationship to 6MWD, if any. With this approach, perhaps health care policy-makers can also create methodical guidelines in approaching depression and helping physicians in avoiding a medical conundrum of whether or not to use medications.

Finally, to address the fundamental shortcomings of health care delivery, an efficient and effective chronic care model should be created for PAH patients, as similar models have shown evidence of improved care for congestive heart failure, diabetes mellitus, and asthma. Six keys elements have been identified in the chronic care model: Health system redesign, decision support, information systems, community involvement, organization, and self-management support for empowering patients [Table 2]. By developing a chronic care model for PAH patients, it will propel physicians toward the establishment of a patient-centered outcome approach. This “patient-centered” outcome approach can empower physicians to embrace web portal-like electronic medical records (EMRs) by allowing effective, efficient, and accurate communication with other team members in patient care. Simple tools embedded in EMRs such as medication dosing or side-effect profile can be helpful in decision-making. Moreover, health portal websites have enabled patients to be more informative about their condition and empower them as well to share responsibility in the management. These simple measures can ensure that patients get optimal care and hence, bring an overall improvement in the treatment outcome.

**SUMMARY**

PAH patients have multiple comorbidities. Depression is an important comorbidity that increases the overall burden of PAH. Accordingly, it is possible to detect depression early by using screening questionnaires and treat it without delay. This may help in reducing distress, improving daily functioning, and leaning toward living a better QoL. While there is a paucity of data about the psychopharmacological agents for PAH patients, we believe that psychological support and PR are an important adjunctive therapy. For that reason, more qualitative research is needed to precisely define their roles in PAH management.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655–65.
2. Galíé N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(Suppl):D60–72.
3. Verma S, Cardenas-Garcia J, Mohapatra PR, Talwar A. Depression in pulmonary arterial hypertension and interstitial lung diseases. N Am J Med Sci 2014;6:240–9.
4. Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
5. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914–9.
6. Wyoobek JM, Lippo G, McLaughlin V, Riba M, Rubenfire M. Psychosocial aspects of pulmonary hypertension: A review. Psychosomatics 2007;48:467–75.
7. McCollister DH. Screening pulmonary hypertension patients for depression. Int J Clin Pract Suppl 2011;4–5.
8. Guillevin L, Armstrong J, Algrighetti R, Howard LS, Rythenius H, Fischer A, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev 2013;22:535–42.
9. Batal O, Khatib OF, Bair N, Abousoussan LS, Minai OA. Sleep, depression, and quality of life in patients with pulmonary hypertension. Lung 2011;189:141–9.
10. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004;126:1452–9.
11. Löwe B, Gräfe K, Ufer C, Kronenke K, Grünig E, Herzog W, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004;66:831–6.
12. Hooper KJ, Pierre A, Dunkley DM, Sigal JJ, Langehein D. Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res 2009;66:221–5.
13. White CA. Cognitive behavioral principles in managing chronic disease. West J Med 2001;175:338–42.
14. McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, et al. Depressive symptoms in pulmonary arterial hypertension: Prevalence and association with functional status. Psychosomatics 2010;51:339.e8.
15. Harzheim D, Klose H, Pinado FP, Ehlenk N, Nagel C, Fischer C, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res 2013;14:104.
16. Tartavoulle TM. A predictive model of the effects of depression, anxiety, stress, 6-minute-walk distance, and social support on health-related quality of life in an adult pulmonary hypertension population. Clin Nurse Spec 2015;29:22–8.
17. U.S. Preventive Services Task Force. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009;151:784–92.
18. Williams JW Jr, Pignone M, Ramirez G, Perez Stellato C. Identifying depression in primary care: A literature synthesis of case-finding instruments. Gen Hosp Psychi 2002;24:225-37.
19. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Wildlitz AC, Rosenzweig EB, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006;19:370-4.
20. Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Faber HW, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest 2013;144:531-41.
21. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 2015;313:2142-51.
22. Mitchell J, Trangle M, Degnan B, Gabert T, Haight B, Kessler D, et al. Adult Depression in Primary Care: Institute for Clinical Systems Improvement; 2013.
23. Kunik ME, Veazey C, Cully JA, Souchek J, Graham DP, Hopko D, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: A randomized controlled trial. Psychol Med 2008;38:385-96.
24. Embuldeniya G, Veinot P, Bell E, Bell M, Nyhof-Young J, Sale JE, et al. The experience and impact of chronic disease peer support interventions: A qualitative synthesis. Patient Educ Couns 2013;92:3-12.
25. Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bosone E. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: An unmet need. Chest 2009;136:597-603.
26. Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: Patients’ experiences. Heart Lung 2005;34:99-107.
27. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al.; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13-64.
28. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 2007;86:30-6.
29. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-15.
30. Talwar A, Sahni S, John S, Verma S, Cárdenas-Garcia J, Kohn N. Effects of pulmonary rehabilitation on Fatigue Severity Scale in patients with lung disease. Pneumonol Alergol Pol 2014;82:534-40.
31. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482-9.
32. Saglam M, Arikan H, Vardar-Yagli N, Calik-Kutukcu E, Inal-Ince D, Savci S, et al. Inspiratory muscle training in pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2013;35:198-206.
33. Jacobson E. Progressive Relaxation. Chicago, IL, USA: University of Chicago Pres; 1938.
34. Li Y, Wang R, Tang J, Chen C, Tan L, Wu Z, et al. Progressive muscle relaxation improves anxiety and depression of pulmonary arterial hypertension patients. Evid Based Complement Alternat Med 2015;2015:792895.
35. Farmer P, Murray M, Hett-Gauthier B. Clinical trials and global health equity. Lancet Global Health Blog. Available from: http://globalhealth.thelancet.com/2013/07/08/clinical‑trials‑and‑global‑health-equity. [Last accessed on 2013 Jul 8].
36. Asch SM, Baker DW, Keesey JW, Broder M, Schonlau M, Rosen M, et al. Does the collaborative model improve care for chronic heart failure? Med Care 2005;43:667-75.
37. Vargas RB, Mangione CM, Asch S, Keesey J, Rosen M, Schonlau M, et al. Can a chronic care model collaborative reduce heart disease risk in patients with diabetes? J Gen Intern Med 2007;22:215-22.
38. Mangione-Smith R, Schonlau M, Chan KS, Keesey J, Rosen M, Louis TA, et al. Measuring the effectiveness of a collaborative for quality improvement in pediatric asthma care: Does implementing the chronic care model improve processes and outcomes of care? Ambul Pediatr 2005;5:75-82.
39. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: Translating evidence into action. Health Aff (Millwood) 2001;20:64-78.